Высокодозная иммуносупрессивная терапия с аутологичной трансплантацией гемопоэтических стволовых клеток при системной аутоиммунной патологии: фокус на системную склеродермию

В мире отмечается рост заболеваемости аутоиммунными болезнями. Системная склеродермия (ССД) чаще встречается у лиц молодого возраста, характеризуясь обширным прогрессирующим фиброзным поражением кожи и других органов, а быстро прогрессирующая диффузная форма ССД в 30 % случаев может приводить к краткосрочному летальному исходу. Высокодозная иммуносупрессивная терапия с аутологичной трансплантацией гемопоэтических столовых клеток (ВИСТ-АТГСК) оказывает множественные иммуноопосредованные эффекты, которые могут привести к уменьшению клинических проявлений и улучшению прогноза у пациентов с ССД. Метод при ССД применяется с 1997 г. В рамках регистра Европейского общества по трансплантации крови и костного мозга выполнено около 900 процедур трансплантации при ССД. В представленной работе проанализированы результаты рандомизированных клинических исследований (ASSIST, ASTIS, SCOT) применения ВИСТ-АТГСК при ССД: представлены характеристики групп пациентов, режимы кондиционирования, эффективность в сравнении со стандартными методами терапии. Также представлены критерии и схема отбора пациентов, показания и противопоказания для проведения процедуры. Представленные данные могут быть использованы для последующего обоснования расширения возможностей оказания помощи пациентам с ССД в Российской Федерации.

1. Wang L., Wang F. S., Gershwin M. E. Human autoimmune diseases: a comprehensive update // J Intern Med. – 2015. – Vol. 278, № 4. – P. 369–95. https://doi.org/10.1111/joim.12395.

2. Scherlinger M., Mertz P., Sagez F. et al. Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014 // Autoimmun Rev. – 2020. – Vol. 19, № 6. – P. 102531. https://doi.org/10.1016/j.autrev.2020.102531.

3. Lerner A., Jeremias P., Matthias T. The world incidence and prevalence of autoimmune diseases is increasing // International Journal of Celiac Disease. – 2015. – Vol. 3, № 4. – P. 151–155. https://doi.org/10.12691/ijcd-3-4-8.

4. Miller F. W. The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention // Curr Opin Immunol. – 2023. – Vol. 80. – P. 102266. https://doi.org/10.1016/j.coi.2022.102266.

5. Cooper G. S., Bynum M. L., Somers E. C. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases // J Autoimmun. – 2009. – Vol. 33, № 3–4. – P. 197–207. https://doi.org/10.1016/j.jaut.2009.09.008.

6. Pisetsky D. S. Pathogenesis of autoimmune disease // Nat Rev Nephrol. – 2023. – Vol. 19, № 8. – P. 509–524. https://doi.org/10.1038/s41581-023-00720-1.

7. Swart J. F., Delemarre E. M., van Wijk F. et al. Haematopoietic stem cell transplantation for autoimmune diseases // Nat Rev Rheumatol. – 2017. – Vol. 13, № 4. – P. 244–256. https://doi.org/10.1038/nrrheum.2017.7.

8. Smilek D. E., Ehlers M. R., Nepom G. T. Restoring the balance: immunotherapeutic combinations for autoimmune disease // Dis Model Mech. – 2014. – Vol. 7, № 5. – P. 503–13. https://doi.org/10.1242/dmm.015099.

9. Alexander T., Farge D., Badoglio M. et al. Hematopoietic stem cell therapy for autoimmune diseases - Clinical experience and mechanisms // J Autoimmun. – 2018. – Vol. 92. – P. 35–46. https://doi.org/10.1016/j.jaut.2018.06.002.

10. Alexander T., Greco R., Snowden J. A. Hematopoietic stem cell transplantation for autoimmune disease // Annu Rev Med. – 2021. – Vol. 72. – P. 215–228. https://doi.org/10.1146/annurev-med-070119-115617.

11. Полушин А. Ю., Залялов Ю. Р., Тотолян Н. А. и др. Высокодозная иммуносупрессивная терапия с аутологичной трансплантацией гемопоэтических стволовых клеток при рассеянном склерозе: перспективы снижения рисков // Анналы клинической и экспериментальной неврологии. – 2022. – Т. 16, № 3. – С. 53–64. https://doi.org/10.54101/ACEN.2022.3.7.

12. Duarte R. F., Labopin M., Bader P. et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019 // Bone Marrow Transplant. – 2019. – Vol. 54, № 10. – P. 1525–1552. https://doi.org/10.1038/s41409-019-0516-2.

13. Afanasyev B. V., Afanasyeva K. S., Barabanshchikova M. V. et al. Indications for hematopoietic stem cell transplantation. 2nd Edition. Based on EBMT Recommendations of 2019 // Cellular Therapy and Transplantation. – 2019. – Vol. 8, № 4. – P. 101–145. https://doi.org/10.18620/ctt-1866-8836-2019-8-4-101-145.

14. Laureys G., Willekens B., Vanopdenbosch L. et al. A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis // Acta Neurol Belg. – 2018. – Vol. 118, № 2. – P. 161–168. https://doi.org/10.1007/s13760-018-0905-0.

15. Burman J., Tolf A., Hägglund H., Askmark H. Autologous haematopoietic stem cell transplantation for neurological diseases // J Neurol Neurosurg Psychiatry. – 2018. – Vol. 89, № 2. – P. 147–155. https://doi.org/10.1136/jnnp-2017-316271.

16. Полушин А. Ю., Залялов Ю. Р., Тотолян Н. А. и др. Высокодозная иммуносупрессивная терапия с аутологичной трансплантацией гемопоэтических стволовых клеток при рассеянном склерозе: современный взгляд на метод (обзор литературы) // Ученые записки Санкт-Петербургского государственного медицинского университета имени академикаИ. П. Павлова. – 2021. – Т. 28, № 4. – С. 9–21. https://doi.org/10.24884/1607-4181-2021-28-4-9-21.

17. Tyndall A., Black C., Finke J. et al. Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation // Lancet. – 1997. – Vol. 349, № 9047. – P. 254. https://doi.org/10.1016/s0140-6736(05)64864-7.

18. Ганич Е. Г., Щукина О. Б., Полушин А. Ю. и др. Высокодозная иммуносупрессивная терапия с аутологичной трансплантацией гемопоэтических стволовых клеток при болезни Крона: обзор литературы // Новые Санкт-Петербургские врачебные ведомости. – 2024. – № 2. – P. 11–24. https://doi.org/10.24884/1609-2201-2024-103-2-11-24.

19. Sykes M., Nikolic B. Treatment of severe autoimmune disease by stem-cell transplantation // Nature. – 2005. – Vol. 435, № 7042. – P. 620–7. https://doi.org/10.1038/nature03728.

20. Tyndall A., Saccardi R. Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: results from phase I/II studies, prospective randomized trials and future directions // Clin Exp Immunol. – 2005. – Vol. 141, № 1. – P. 1–9. https://doi.org/10.1111/j.1365-2249.2005.02806.x.

21. Farge D., Marolleau J. P., Zohar S. et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study // Br J Haematol. – 2002. – Vol. 119, № 3. – P. 726–39. https://doi.org/10.1046/j.1365-2141.2002.03895.x.

22. Snowden J. A., Sharrack B., Akil M. et al. Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases - a guide for the generalist // Clin Med (Lond). – 2018. – Vol. 18, № 4. – P. 329–334. https://doi.org/10.7861/clinmedicine.18-4-329.

23. Poudel D. R., Derk C. T. Mortality and survival in systemic sclerosis: a review of recent literature // Curr Opin Rheumatol. – 2018. – Vol. 30, № 6. – P. 588–593. https://doi.org/10.1097/BOR.0000000000000551.

24. Bergamasco A., Hartmann N., Wallace L., Verpillat P. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease // Clin Epidemiol. – 2019. – Vol. 11. – P. 257–273. https://doi.org/10.2147/CLEP.S191418.

25. Tyndall A. J., Bannert B., Vonk M. et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database // Ann Rheum Dis. – 2010. – Vol. 69, № 10. – P. 1809– 15. https://doi.org/10.1136/ard.2009.114264.

26. Denton C. P., Khanna D. Systemic sclerosis // Lancet. – 2017. – Vol. 390, № 10103. – P. 1685–1699. https://doi.org/10.1016/S0140-6736(17)30933-9.

27. Ramaswamy S., Jain S., Ravindran V. Hematopoietic stem cell transplantation for auto immune rheumatic diseases // World J Transplant. – 2016. – Vol. 6, № 1. – P. 199–205. https://doi.org/10.5500/wjt.v6.i1.199.

28. Burt R. K., Traynor A., Statkute L. et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus // JAMA. – 2006. – Vol. 295, № 5. – P. 527–35. https://doi.org/10.1001/jama.295.5.527.

29. Oyama Y., Barr W. G., Statkute L. et al. Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis // Bone Marrow Transplant. – 2007. – Vol. 40, № 6. – P. 549–55. https://doi.org/10.1038/sj.bmt.1705782.

30. Burt R. K., Han X., Quigley K. et al. Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days // Bone Marrow Transplant. – 2021. – Vol. 56, № 1. – P. 50–59. https://doi.org/10.1038/s41409-020-0978-2.

31. Storek J., Zhao Z., Lin E. et al. Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases) // Clin Immunol. – 2004. – Vol. 113, № 3. – P. 285–98. https://doi.org/10.1016/j.clim.2004.07.006.

32. Henes J., Glaeser L., Kötter I. et al. Analysis of anti-topoisomerase I antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation // Rheumatology (Oxford). – 2017. – Vol. 56, № 3. – P. 451–456. https://doi.org/10.1093/rheumatology/kew319.

33. Glaeser L., Henes J., Kötter I. et al. Molecular recognition patterns of anti-topoisomerase I-antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation // Clin Exp Rheumatol. – 2018. – Vol. 36, Suppl 113, № 4. – P. 28–35.

34. Tsukamoto H., Nagafuji K., Horiuchi T. et al. Analysis of immune reconstitution after autologous CD34+ stem/ progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4+ T cells // Rheumatology (Oxford). – 2011. – Vol. 50, № 5. – P. 944–52. https://doi.org/10.1093/rheumatology/keq414.

35. Levin D., Osman M. S., Durand C. et al. Hematopoietic cell transplantation for systemic sclerosis-a review // Cells. – 2022. – Vol. 11, № 23. – P. 3912. https://doi.org/10.3390/cells11233912.

36. Gernert M., Tony H. P., Schwaneck E. C. et al. Autologous hematopoietic stem cell transplantation in systemic sclerosis induces long-lasting changes in B cell homeostasis toward an anti-inflammatory B cell cytokine pattern // Arthritis Res Ther. – 2019. – Vol. 21, № 1. – P. 106. https://doi.org/10.1186/s13075-019-1889-8.

37. Sullivan K. M., Shah A., Sarantopoulos S., Furst D. E. Review: Hematopoietic stem cell transplantation for scleroderma: effective immunomodulatory therapy for patients with pulmonary involvement // Arthritis Rheumatol. – 2016. – Vol. 68, № 10. – P. 2361–71. https://doi.org/10.1002/art.39748.

38. Burt R. K., Shah S. J., Dill K. et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial // Lancet. – 2011. – Vol. 378, № 9790. – P. 498–506. https://doi.org/10.1016/S0140-6736(11)60982-3.

39. van Laar J. M., Farge D., Sont J. K. et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis. – P. a randomized clinical trial // JAMA. – 2014. – Vol. 311, № 24. – P. 2490–8. https://doi.org/10.1001/jama.2014.6368.

40. Sullivan K. M., Goldmuntz E. A., Keyes-Elstein L. et al. Myeloablative autologous stem-cell transplantation for severe scleroderma // N Engl J Med. – 2018. – Vol. 378, № 1. – P. 35–47. https://doi.org/10.1056/nejmoa1703327.

41. Atkins H. L., Muraro P. A., van Laar J. M., Pavletic S.Z. Autologous hematopoietic stem cell transplantation for autoimmune disease – is it now ready for prime time? // Biol Blood Marrow Transplant. – 2012. – Vol. 18, № 1 Suppl. – P. S177–83. https://doi.org/10.1016/j.bbmt.2011.11.020.

42. Del Papa N., Onida F., Zaccara E. et al. Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis // Bone Marrow Transplant. – 2017. – Vol. 52, № 1. – P. 53–58. https://doi.org/10.1038/bmt.2016.211.

43. Del Papa N., Cavalli S., Rindone A. et al. Long-term outcome of autologous haematopoietic stem cell transplantation in patients with systemic sclerosis: a comparison with patients treated with rituximab and with traditional immunosuppressive agents // Arthritis Res Ther. – 2024. – Vol. 26, № 1. – P. 182. https://doi.org/10.1186/s13075-024-03408-4.

44. Zare Moghaddam M., Mousavi M. J., Ghotloo S. Stem cell-based therapy for systemic sclerosis // Rheumatol Adv Pract. – 2023. – Vol. 7, № 3. – P. rkad101. https://doi.org/10.1093/rap/rkad101.

45. Del Papa N., Pignataro F., Zaccara E. et al. Autologous Hematopoietic Stem Cell Transplantation for Treatmentof Systemic Sclerosis // Front Immunol. – 2018. – Vol. 9. – P. 2390. https://doi.org/10.3389/fimmu.2018.02390.

46. Hosing C., Nash R., McSweeney P. et al. Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States // Biol Blood Marrow Transplant. – 2011. – Vol. 17, № 5. – P. 674–81. https://doi.org/10.1016/j.bbmt.2010.08.003.

47. Guillaume-Jugnot P., Badoglio M., Labopin M. et al. Autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease adult patients in France: analysis of the long-term outcome from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) // Clin Rheumatol. – 2019. – Vol. 38, № 5. – P. 1501–1511. https://doi.org/10.1007/s10067-019-04435-2.

48. Strunz P. P., Froehlich M., Gernert M. et al. Immunological adverse events after autologous hematopoietic stem cell transplantation in systemic sclerosis patients // Front Immunol. – 2021. – Vol. 12. – P. 723349. https://doi.org/10.3389/fimmu.2021.723349.

49. Daikeler T., Labopin M., Di Gioia M. et al. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party // Blood. – 2011. – Vol. 118, № 6. – P. 1693–8. https://doi.org/10.1182/blood-2011-02-336156.

50. Henes J. C., Schmalzing M., Vogel W. et al. Optimization of autologous stem cell transplantation for systemic sclerosis - a single-center longterm experience in 26 patients with severe organ manifestations // J Rheumatol. – 2012. – Vol. 39, № 2. – P. 269–75. https://doi.org/10.3899/jrheum.110868.

51. Kowal-Bielecka O., Fransen J., Avouac J. et al. Update of EULAR recommendations for the treatment of systemic sclerosis // Ann Rheum Dis. – 2017. – Vol. 76, № 8. – P. 1327–1339. https://doi.org/10.1136/annrheumdis-2016-209909.

52. Burt R. K., Farge D. Systemic sclerosis: Autologous HSCT is efficacious, but can we make it safer? // Nat Rev Rheumatol. – 2018. – Vol. 14, № 4. – P. 189–191. https://doi.org/10.1038/nrrheum.2018.34.

53. Snowden J. A., Badoglio M., Labopin M. et al. Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases // Blood Adv. – 2017. – Vol. 1, № 27. – P. 2742–2755. https://doi.org/10.1182/bloodadvances.2017010041.

54. Domsic R. T., Rodriguez-Reyna T., Lucas M. et al. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma // Ann Rheum Dis. – 2011. – Vol. 70, № 1. – P. 104–9. https://doi.org/10.1136/ard.2009.127621.

55. Maurer B., Graf N., Michel B. A. et al. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database // Ann Rheum Dis. – 2015. – Vol. 74, № 6. – P. 1124–31. https://doi.org/10.1136/annrheumdis-2014-205226.

56. Steen V. D., Medsger T. A. Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival // Arthritis Rheum. – 2001. – Vol. 44, № 12. – P. 2828–35. https://doi.org/10.1002/1529-0131(200112)44:12<2828::aidart470>3.0.co;2-u.

57. van den Hoogen F., Khanna D., Fransen J. et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative // Ann Rheum Dis. – 2013. – Vol. 72, № 11. – P. 1747–55. https://doi.org/10.1136/annrheumdis-2013-204424.

58. Farge D., Ait Abdallah N., Marjanovic Z., Del Papa N. Autologous stem cell transplantation in scleroderma // Presse Med. – 2021. – Vol. 50, № 1. – P. 104065. https://doi.org/10.1016/j.lpm.2021.104065.